Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | RAD52 | P43351 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29826892 | 0.82 | TSHR (0.46) | TSHRKMT2AMEN1NPC1RAB9A | |
| SCHEMBL18725641 | 0.82 | TSHR (0.46) | TSHRKMT2AMEN1NPC1RAB9A | |
| Ethoxycarbonyl Group SCHEMBL27710458 | 0.82 | TSHR (0.48) | TSHRKMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29582475 | 0.81 | MEN1 (0.64) | KMT2AMEN1MAPK10GFERNPC1 | |
| SCHEMBL626575 | 0.81 | MEN1 (0.64) | KMT2AMEN1MAPK10GFERNPC1 | |
| SCHEMBL16897029 | 0.80 | MAPK10 (0.55) | TSHRKMT2AMEN1MAPK10NPC1 | |
| SCHEMBL31138002 | 0.79 | MEN1 (0.61) | KMT2AMEN1MAPK10GFERNPC1 | |
| SCHEMBL3950825 | 0.79 | NPC1 (0.51) | TSHRKMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29618407 | 0.79 | NPC1 (0.51) | TSHRKMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3697322 | 0.79 | KDR (0.45) | KMT2ANPC1RAB9AMAPTRAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108373416-B | Method for synthesizing diarylamine by photo/nickel concerted catalysis | 陕西师范大学 | 2020-11-17 | — | — | CN | disclosed |
| CN-109715612-A | SOMATOSTATIN MODULATORS AND USES THEREOF | 克林提克斯医药股份有限公司 | 2019-05-03 | — | — | CN | disclosed |
| EP-2391605-B1 | SCRIPTAID ISOSTERES AND THEIR USE IN THERAPY | KARUS THERAPEUTICS LTD (GB) | 2017-11-08 | — | — | EP | disclosed |
| US-9340503-B2 | Scriptaid isosteres and their use in therapy | KARUS THERAPEUTICS, LIMITED (GB) | 2016-05-17 | — | — | US | disclosed |
| US-9340503-B2 | Scriptaid isosteres and their use in therapy | KARUS THERAPEUTICS, LIMITED (GB) | 2016-05-17 | — | — | US | disclosed |
| US-9060515-B2 | Heterocyclic urea compounds | BIOTA EUROPE LTD. (GB) | 2015-06-23 | — | — | US | disclosed |
| US-20140323486-A1 | HETEROCYCLIC UREA COMPOUNDS | SPERO GYRASE, INC. | 2014-10-30 | — | — | US | disclosed |
| US-20140235671-A1 | SCRIPTAID ISOSTERES AND THEIR USE IN THERAPY | KARUS THERAPEUTICS LIMITED (GB) | 2014-08-21 | — | — | US | disclosed |
| US-20140235671-A1 | SCRIPTAID ISOSTERES AND THEIR USE IN THERAPY | KARUS THERAPEUTICS LIMITED (GB) | 2014-08-21 | — | — | US | disclosed |
| WO-2010086646-A1 | SCRIPTAID ISOSTERES AND THEIR USE IN THERAPY | KARUS THERAPEUTICS LIMITED (GB) | 2010-08-05 | — | — | WO | disclosed |
| US-20090256468-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-10-15 | — | — | US | disclosed |
| US-20090256468-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-10-15 | — | — | US | disclosed |
| EP-2096108-A1 | Novel organic electroluminescent compounds and organic electroluminscent device using the same | Gracel Display Inc. (KR) | 2009-09-02 | — | — | EP | disclosed |
| WO-2009022171-A1 | PYRIDINYIIOXY PYRIDINES AS ALK5 INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | WO | disclosed |
| EP-2010487-A1 | 5-AMIDO-2-CARBOXAMIDE INDOLES | F. Hoffmann-Roche AG (CH) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007115938-A1 | 5-AMIDO-2-CARBOXAMIDE INDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-10-18 | — | — | WO | disclosed |
| US-20060293503-A1 | Polyaminopyridines and method for producing same | SUMITOMO SEIKA CHEMICALS CO., LTD (JP) | 2006-12-28 | — | — | US | disclosed |
| EP-1669390-A1 | POLYAMINOPYRIDINES AND METHOD FOR PRODUCING SAME | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 2006-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235671-A1 | SCRIPTAID ISOSTERES AND THEIR USE IN THERAPY | QARS1, C1QBP, QTRT1 | TSHR 1920/4885KMT2A 1846/4885MEN1 3591/4885 |
| US-20140323486-A1 | HETEROCYCLIC UREA COMPOUNDS | UMPS, URB2, UROD | TSHR 3413/4885KMT2A 3774/4885MEN1 3358/4885 |
| US-20090256468-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | ORMDL3, OCIAD1, OCIAD2 | TSHR 4697/4885KMT2A 2666/4885MEN1 4282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.